Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials

Trial Profile

Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Allergopharma
  • Most Recent Events

    • 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
    • 26 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top